StreetAlpha.app
Home › Stocks › NGNE

Neurogene Inc. (NGNE)

$22.15
▼ −3.40%
LAST CLOSE · NOV 20

Neurogene develops genetic medicines for rare neurological diseases, with its lead candidate aimed at Rett syndrome. It last closed at $22.15 on Nov 20, down 3.40% on the day. The next earnings report for NGNE is expected around Tue, Mar 23, 2027. For the quarter ended Sep 2026, NGNE reported EPS of -$1.05. Over its last 8 reports the stock moved an average of 4.9% the session after earnings. Over the last 12 months NGNE insiders bought $0 of stock on the open market and sold $1.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is NGNE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NGNE.

Key Stats

Last 12 months
Results
Net income
−$119.2M
EPS (diluted)
−$5.03
Free cash flow
−$97.5M
Valuation
Market cap
$458.5M
20.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$78.9M
At Sep 30
Shareholder equity
$354.8M
Shares outstanding
20.7M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $925K$925KFY2024FY2025: $0$0FY2025

From NGNE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 23
Estimated date · Time not announced
Reported EPS
-$1.05
Quarter ended Sep 2026
Year ago EPS
-$0.99
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.99Dec '24Mar 2025: -$1.08Mar '25Jun 2025: -$1.05Jun '25Sep 2025: -$0.99Sep '25Dec 2025: -$1.13Dec '25Mar 2026: -$1.39Mar '26Jun 2026: -$1.53Jun '26Sep 2026: -$1.05Sep '26Latest -$1.05
Revenue by quarter
Dec 2024: $0Dec '24Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Latest $0
How NGNE moved after its last 8 reports
Average move the session after a report ±4.9%
Nov 9, 2026Time not announced+2.7%
Aug 11, 2026Time not announced−2.0%
May 12, 2026After the close+3.4%
Mar 24, 2026Time not announced+8.0%
Nov 13, 2025After the close−14.0%
Aug 11, 2025After the close−5.5%
May 9, 2025Time not announced−1.8%
Mar 24, 2025After the close+1.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NGNEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NGNE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NGNE

Technical Analysis

NGNE · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 15% below its 20 day and 21% below its 50 day average. It is 28% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $21.82, and the nearest resistance the Pivot at $22.36.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.9%/day
Key levels
$43.6652 week high+97.1%
$31.77100 day average+43.4%
$28.31200 day average+27.8%
$26.94Swing high (Oct 21)+21.6%
$26.7850 day average+20.9%
$25.4020 day average+14.7%
$22.69Pivot R1+2.4%
$22.36Pivot+0.9%
$22.15Last close
$21.82Pivot S1−1.5%
$21.05Swing low (Oct 14)−5.0%
$15.9352 week low−28.1%
Indicators
RSI (14)35.34Weak, oversold below 30Neutral
MACD-1.19Below its signal lineBearish
Stochastic8.4Near the bottom of its rangeOversold
ADX (14)14.7No clear trend
Williams %R-98.2Oversold below −80, overbought above −20Oversold
CCI (20)-118.0Oversold below −100, overbought above 100Oversold
Rate of change−12.5%Change over 10 sessionsBearish
ATR (14)$1.96Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NGNE

What happened before

See how NGNE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NGNE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NGNE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NGNEHow many large options trades hit NGNE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NGNE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 33 selling
  • ▲Held by funds +32.4 pts
  • ▲Funds holding +20
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding132112+17.9%
In funds' top 1034−25.0%
Held by funds116.0%83.6%+32.4 pts
New / increased32 / 6122 / 37+57.6%
Reduced / sold out21 / 1231 / 4−5.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NGNE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NGNE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.1M9 sales · 4 insiders
100% of the selling was under pre-arranged trading plans.
2026-02 sold $121K2026-03 sold $373K2026-05 sold $300K2026-07 sold $340KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 7Christine Mikail CvijicPresident and CFOSale plan4,800$36.12$173K
Jul 2Christine Mikail CvijicPresident and CFOSale plan4,800$34.71$167K
May 6Christine Mikail CvijicPresident and CFOSale plan9,600$31.25$300K
Mar 26Christine Mikail CvijicPresident and CFOSale plan2,558$21.62$55K
Mar 26Rachel McMinnCEOSale plan3,352$22.07$74K
Mar 26Julie JordanChief Medical OfficerSale plan828$21.89$18K
Every insider buy and sale for NGNE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NGNE insider trades →

From SEC Form 4 filings by NGNE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NGNE is in one of them and how their past NGNE trades turned out.

NGNE in the AI portfolios
Loading…

NGNE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NGNE in an article yet. Here's the latest on the wider market.

NGNE in the news

About Neurogene

Neurogene is a biotechnology company based in New York that develops genetic medicines for rare neurological diseases. Its lead product candidate, NGN-401, is being studied for Rett syndrome, a severe disease that affects brain development. The company uses its proprietary EXACT technology to control how much therapeutic gene is produced in key areas of the brain. None of its products are approved for sale yet, so it does not currently generate product revenue.

Headquarters
New York, NY